Press release
Human Immunodeficiency Virus (HIV) Drugs Market Analysis with Competitive Landscape and Forecast 2025: Bristol-Myers Squibb, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim
industry/Healthcare
Download PDF Brochure of Research Report: https://www.polarismarketresearch.com/industry-analysis/global-human-immunodeficiency-virus-hiv-drugs-market/request-for-free-sample
Report Summary
Human Immune-deficiency Virus (HIV) is the most extensive and incurable disease, causes HIV infection and over time Acquired Immunodeficiency Syndrome (AIDS). There has been a significant rise in number of HIV population worldwide. According to the World Health Organization (WHO) 2013, HIV ranked 6th among the global deaths throughout the world, with approximately 1,776,270 deaths in 2009. HIV is the 2nd most common cause of death after cancer. According to the same reports in 2009, more than 1,780,000 global death case were filed.
However, HIV antivirals is the largest segment of drug in the HIV infection market. Pharmaceutical companies are continuously focusing on the research and development for developing new drugs in the term to cure HIV infection by improving the person’s lifestyle supressing infection virus throughout the life.
Increasing R&D in the area of HIV infection and growing demand for the drugs bolstering the HIV drugs market.
In the recent time, rising prevalence of HIV infection is on the huge surge. According to the World Health Organizations (WHO) 2015, globally around 37 million number of people were found to be infected with HIV. Thus, rising incidence of HIV infected people and the demand for the drugs to treat the disease are the major factors driving the global market. Additionally, Rise in the incidence of unprotected sex has led to increase in the prevalence of HIV/AIDS, further demanding cure drugs.
Global Human Immunodeficiency Drugs (HIV) Market Taxonomy
The global Human Immunodeficiency (HIV) Drugs Market is segmented on the basis of Drug Class, Distribution channel, and geography.
On the basis of drug class, the global Human Immunodeficiency (HIV) drugs market is segmented into:
• Nucleoside reverse transcriptase inhibitors (NRTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs),
• Entry & Fusion Inhibitors
• Integrase Inhibitors
• Protease Inhibitors (PIs)
• Combination Class Drugs
On the basis of distribution channel, the global Human Immunodeficiency (HIV) drugs market is segmented into:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
Complete Summary of this report @ https://www.polarismarketresearch.com/industry-analysis/global-human-immunodeficiency-virus-hiv-drugs-market/
Geographically, the global Human Immunodeficiency (HIV) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Key players in global Human Immunodeficiency (HIV) drugs market:
• Bristol-Myers Squibb Company
• ViiV Healthcare (Pfizer Inc.)
• GlaxoSmithKline plc
• Gilead Sciences Inc.
• Boehringer Ingelheim (C.H. Boehringer Sohn AG & Ko. KG)
• Hoffmann-La Roche AG
• Abbott Laboratories Inc.
• Janssen Therapeutics
• Merck & Co. Inc.
• Cipla Limited
About us Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities.
Contact us-
Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Immunodeficiency Virus (HIV) Drugs Market Analysis with Competitive Landscape and Forecast 2025: Bristol-Myers Squibb, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim here
News-ID: 1333391 • Views: …
More Releases from Polaris Market Research & Consulting
Genetic Analysis Market Poised to Achieve USD 45.10 Billion by 2032, Growing at …
𝐀𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟐𝟏.𝟑𝟗 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟒𝟓.𝟏𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟖.𝟔𝟎% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.
The growing prevalence of early & rapid diagnosis and rising awareness of personalized medicines are the primary factors boosting the market growth. Besides, a significant rise in healthcare investments in major nations…
Biobased Polyvinyl Chloride Market to Expand to US$ 3,488.72 Million by 2032, Re …
The capacity to utilize renewable raw materials such as plant-dependent origin renders it an alluring option for industries seeking to assort their raw material origins, which is shaping the industry's future. Our thorough analysis of the Biobased Polyvinyl Chloride Market covers the industry size, share, recent developments, and top trends. Besides, we have in-depth examined all the major regions and segments.
𝐔𝐧𝐥𝐨𝐜𝐤 𝐨𝐮𝐫 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨𝐝𝐚𝐲: https://www.polarismarketresearch.com/industry-analysis/biobased-polyvinyl-chloride-market/request-for-sample
𝐓𝐡𝐞 𝐁𝐢𝐨𝐛𝐚𝐬𝐞𝐝 𝐏𝐨𝐥𝐲𝐯𝐢𝐧𝐲𝐥…
Cell Dissociation Market Set to Surge to USD 1,161.06 Million by 2032, with Annu …
𝐀𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐜𝐞𝐥𝐥 𝐝𝐢𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐢𝐨𝐧 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟑𝟓𝟔.𝟕𝟔 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟏,𝟏𝟔𝟏.𝟎𝟔 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟒.𝟎% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.
Technological progressions, growing demand for cell-dependent assays and remedies, growing funding in research and development, and escalating approval of regenerative medicines are prominent trends shaping the industry's future. Our thorough analysis of…
Surface Mount Technology Market Share Reach USD 10.00 Billion by 2032 | Growing …
𝐓𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐬𝐭𝐮𝐝𝐲 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐯𝐞𝐚𝐥𝐬 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐒𝐮𝐫𝐟𝐚𝐜𝐞 𝐌𝐨𝐮𝐧𝐭 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐰𝐢𝐭𝐧𝐞𝐬𝐬 𝐚 𝐬𝐭𝐞𝐚𝐝𝐲 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝 𝐚𝐧𝐧𝐮𝐚𝐥 𝐠𝐫𝐨𝐰𝐭𝐡 𝐫𝐚𝐭𝐞 (𝐂𝐀𝐆𝐑) 𝐨𝐟 8.30% 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝 𝐟𝐫𝐨𝐦 2024 𝐭𝐨 2032. 𝐓𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 4.88 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐭𝐨 𝐔𝐒𝐃 10.00 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2032. The growing trend of miniaturization in the electronics sector has led to increased…
More Releases for HIV
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus.
Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral…
